from youarewithinthenorms.com
NORMAN J CLEMENT RPH., DDS, NORMAN L. CLEMENT PHARM-TECH, MALACHI F. MACKANDAL PHARMD, BELINDA BROWN-PARKER, IN THE SPIRIT OF JOSEPH SOLVO ESQ., INC., SPIRIT OF REV. IN THE SPIRIT OF WALTER R. CLEMENT BS., MS, MBA. HARVEY JENKINS, MD, PH.D., IN THE SPIRIT OF C.T. VIVIAN, JELANI ZIMBABWE CLEMENT, BS., M.B.A., IN THE SPIRIT OF THE HON. PATRICE LUMUMBA, IN THE SPIRIT OF ERLIN CLEMENT SR., EVELYN J. CLEMENT, IN THE SPIRIT OF WALTER F. WRENN III., MD., JULIE KILLINGSWORTH, RENEE BLARE, RPH, DR. TERENCE SASAKI, MD LESLY POMPY MD., CHRISTOPHER RUSSO, MD., NANCY SEEFELDT, IN THE SPIRIT OF WILLIE GUINYARD BS., JOSEPH WEBSTER MD., MBA, BEVERLY C. PRINCE MD., FACS., NEIL ARNAND, MD., RICHARD KAUL, MD., IN THE SPIRIT OF LEROY BAYLOR, JAY K. JOSHI MD., MBA, AISHA GARDNER, ADRIENNE EDMUNDSON, ESTER HYATT PH.D., WALTER L. SMITH BS., IN THE SPIRIT OF BRAHM FISHER ESQ., MICHELE ALEXANDER MD., CUDJOE WILDING BS, MARTIN NJOKU, BS., RPH., IN THE SPIRIT OF DEBRA LYNN SHEPHERD, BERES E. MUSCHETT, STRATEGIC ADVISORS
biological complexity of addiction and the specific ways the human liver processes opiates.
Drawing on the works of the late Dr. Walter F. Wrenn, this article challenges the medical validity of using Morphine Milligram Equivalents (MME) to dictate clinical practice. He argued that current regulatory standards fail to account for the biological complexity of addiction and the specific ways the human liver processes opiates.
The MME Fallacy: Rethinking Opioid Physiology
By comparing pain management to diabetes care, the text suggests that effective treatment requires a physiological understanding of how receptors function rather than dosing metrics.
In this discussion, Dr. Wrenn advocates for a science-based approach to pharmacology to replace what it views as the punitive and unscientific oversight of government drug enforcement. than arbitrary.
THE MME MEASUREMENT PROBLEM
the physiological framework and essential components that reinforce survival
key insight:
Understanding physiology is as vital for treating addiction as it is for treating diabetes. Just as we do not manage blood sugar through “dose-dependency” myths but through a rigorous understanding of insulin and glucose metabolism, we must apply the same clinical rigor to the biology of opiates.
The brain’s reward system (mesolimbic pathway) is a network of structures—primarily the ventral tegmental area (VTA) and nucleus accumbens—that reinforces survival-essential behaviors like eating and social interaction by releasing dopamine.
This creates feelings of pleasure and motivation, driving the repetition of actions. Key components include dopamine, neurotransmitters, and brain regions that regulate memory, emotion, and decision-making.
Here are some of the key components:
•Ventral Tegmental Area (VTA): Produces and releases dopamine, functioning as the engine of the reward system.
•Nucleus Accumbens (NAc): The central processor of pleasure and motivation.
•Prefrontal Cortex (PFC): Handles decision-making, planning, and impulse control.
•Amygdala: Processes emotions associated with the reward.
•Hippocampus: Records memories of the environmental context of the reward.
Dopamine also has a big role in this process. Which acts as the primary chemical messenger for reward. It does not just signal pleasure but also “incentive salience,” or the motivation/craving to pursue a reward. It marks stimuli as valuable, encouraging the brain to prioritize them.
THE PATHOLOGY OF ADDICTION
Here are some examples of core mechanisms:
•Dopamine Release: Acts as a signal marking experiences as positive and worth repeating.
•Motivation & Learning: The system doesn’t just produce pleasure, but motivates “wanting” and drives learning (classical/operant conditioning).
•Addiction Mechanism: Artificial stimuli, such as drugs, can cause unnatural dopamine surges, causing the system to prioritize these substances over natural rewards.
•Neurotransmitter Roles: While dopamine is central, other chemicals like opioids are also involved in the “liking” aspect of reward.
Science Primer The Biology of Opiates and Recovery
Introduction: Shifting the Perspective on Addiction
In the realm of clinical medical science, we must move past the reductive and unscientific metrics that have dominated addiction discourse. For too long, the “missing link” in treating opiate use disorder has been the reliance on Morphine Milligram Equivalents (MME)—a metric that provides a false sense of precision while ignoring the fundamental biological realities of drug absorption, receptor affinity, and liver metabolism.
To treat addiction effectively, we must stop viewing it through the lens of social stigma or simple arithmetic myths and start addressing the physiological processes of the human body.
The failure to recognize that addiction is a biological process rather than a mere behavioral choice has led to the tyranny of unscientific prescribing limits. By shifting our perspective to the microscopic sites where these drugs interact with the nervous system, we can align our clinical practice with reality.
——————————————————————————–
The Gateway: How Opiate Receptors Function
Opiate receptors are the primary attachment points for medications, functioning as the gateway for both stabilization and recovery. Within this system, the Mu receptor is the critical site of action.
However, the interaction is more complex than a simple “on/off” switch. It involves distinct phases of activation. Suboxone (buprenorphine/naloxone) is engineered to interact with these receptors as a partial agonist/antagonist, ensuring that the physiological need is met without triggering the destructive phases of the receptor.
| Receptor Interaction | Effect on the Body |
| Mu Receptor Activation | Traditional opiates fully activate the receptor, triggering the specific phase responsible for the experience of euphoria (the “high”). |
| Mu Receptor Blockage | Suboxone attaches to the receptor to prevent other opiates from connecting; crucially, the euphoric phase of the Mu receptor is not activated during this process. |
While receptors are the final destination for these molecules, the liver acts as the engine that dictates the “bioavailability” or the actual amount of medication that reaches these sites.
——————————————————————————–
The Engine: Liver Detoxification and the “Missing Link”
A central question in clinical science is why patients require increasing doses to achieve stability. The answer lies in the liver’s detoxification rate. The liver is a dynamic organ that adapts to the presence of substances by accelerating its processing speed. This metabolic acceleration is the primary driver of dose requirements, a fact routinely ignored by MME-based guidelines.
The sequence of physiological events occurs as follows:
- Ingestion: The substance enters the systemic circulation.
- Metabolic Response: The liver identifies the substance and initiates detoxification.
- Increased Detoxification Rate: With repeated exposure, the liver’s metabolic engine becomes more efficient, breaking down the substance at an accelerated rate.
- Physiological Necessity of Higher Doses: Because the liver clears the drug more rapidly, higher doses than are presently prescribed are often a physiological necessity to maintain the plasma levels required to suppress cravings and withdrawal.
This understanding of the liver’s metabolic speed is exactly why medications like Suboxone must be processed and prescribed according to individual biology rather than arbitrary administrative norms.
——————————————————————————–
The Safety Valve: Suboxone and the ‘Ceiling Effect’
Suboxone is a sophisticated pharmaceutical intervention designed to stabilize the patient’s internal chemistry while incorporating essential safety mechanisms. By combining two distinct components, it addresses both the physiological drive for opiates and the acute risk of respiratory depression.
| Component | Primary Function |
| Buprenorphine | A partial agonist that attaches firmly to receptors, blocking full-agonist opiates from binding and preventing the physical drive of addiction. |
| Naloxone | An antagonist included to prevent the overdose process, acting as a critical safety barrier. |
The score Behind the Prescription, the digital third person in the exam room
The “Ceiling Effect” is perhaps the most significant safety feature for the patient; it ensures that after a specific threshold is reached, the pharmacological effect plateaus. This prevents the life-threatening respiratory depression associated with traditional opiates. These chemical functions are not merely “harm reduction” tools; they are the pillars of a successful medical treatment plan designed to restore the patient to homeostasis.
Clinical Synthesis: Treating Addiction Like a Science
When we apply scientific rigor to addiction, we see that it mirrors the management of other chronic metabolic conditions like diabetes. Our success in diabetes care stems from targeting specific physiological failures:
- Metformin is utilized to prevent the liver from overproducing sugar between meals.
- Insulin is administered when the body’s beta cells can no longer meet physiological demands.
- SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors) are used to excrete excess sugar in the urine, removing circulating glucose that has not been taken up by the mitochondria for energy.
The “So What?” of this comparison is clear: just as a diabetic requires specific doses to manage sugar, an addiction patient requires high enough plasma levels of buprenorphine to prevent the biological drive of cravings. Current prescribing norms often fall short of these clinical requirements by overlooking the liver’s metabolic engine.
Future Takeaways for Addiction Science:
- Physiological Reality: We must abandon the MME metric, which ignores drug absorption and receptor affinity, in favor of a model that prioritizes individual metabolic rates.
- Evidence-Based Processing: Clinical success depends on analyzing medications based on how they are actually “processed” by the body, rather than adhering to simple arithmetic myths.
- The Norms of Health: The ultimate goal of buprenorphine therapy is to maintain correct plasma levels so the patient can function “within the norms” of healthy, productive life.
By illuminating the biology underlying addiction treatment, we transform the treatment of addiction from a misunderstood social issue into a precise and effective clinical discipline. Overall, This evolutionarily ancient pathway helps organisms survive by reinforcing beneficial behaviors
Learn more: https://lnkd.in/gfJSc9Jx
Dr. Wrenn was an active member of the National Medical Association, a trustee on its board for 6 years. He held leadership roles, including: 18th Second District Representative, Omega Psi Phi Fraternity, Inc. (1982-84), President, Medical Society of Eastern Pennsylvania (1997–98), President, Jefferson Medical College Alumni Association (2004), and President, Keystone State Medical Society (2010–2021).
A was a proud 60-year member of Omega Psi Phi Fraternity, Inc., Mu Omega Chapter; he was deeply committed to mentorship and community uplift. He was also a longtime member of Vine Memorial Baptist Church, where he served in music ministry and Sunday School leadership.
Known for his wit, wisdom, and warmth, “Doc” was a gifted storyteller and lifelong learner. He earned a Black Belt in Taekwondo and remained intellectually curious throughout his life.
He is survived by his wife of 48 years, Minister Glenda L. Wrenn, and children: Walter, Karen, Jonathan (Joy), Katira (Frederick), Glenda (Akil), and Gregory; as well as grandchildren, great-grandchildren, and a host of extended family and friends. He was predeceased by two children, Kathy and Aziza.
A celebration of life will be held on Saturday, September 6, 2025, at Vine Memorial Baptist Church, 5600 Girard Avenue, Philadelphia. Omega Service begins at 10:00 a.m., followed by the funeral at 11:00 a.m. Services are entrusted to Wood Funeral Home.
TO CASH APP:$docnorm
ZELLE 3135103378
ALL WATCHED OVER BY MACHINES OF LOVING GRACE
BE SURE TO DONATE TO THE MARK IBSEN GOFUNDME DEFENSE FUND, WHERE THE SON ALWAYS RISES!!!
FOR NOW, YOU ARE WITHIN
THE NORMS
REFERENCES:
